ERBB2 and breast carcinoma: Of note, another phase II/III trial evaluating the benefit of paclitaxel in combination with BKM120 or placebo (BELLE-4, NCT01572727) in first-line advanced HER2-negative breast cancer was recently terminated after an interim analysis due to futility.